Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Pr Andreas Wedrich

In this page

Member info

Pr Andreas Wedrich

Representative

Austria

Team

Dr Haleh Aminfar

Austria

Neuro-Ophthalmology Rare Diseases (WG2)
See more

Pr Jutta Berglöff

Austria

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
See more

Dr Thomas Georgi

Austria

CPMS & Digital Medecine (TWG10), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Manuel Großpötzl

Austria

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
See more

Dr Mona Schneider

Austria

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Sanja Strini

Austria

Neuro-Ophthalmology Rare Diseases (WG2)
See more

Dr Katharina Valentin

Austria

National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)
See more

HCP Center

The Styrian Hospital Corporation (KAGes) is an organisation which manages 19 hospitals in Styria on 22 locations, with 1 university clinic, 1 center...

contact

University Hospital Graz, Department of Neuro-Ophthalmology, Graz, Austria

Auenbruggerplatz 4
8036 Graz
Austria

Clinical trials

NCT05537220 Active, Not recruiting

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

Interventional
See the trial
voir la fiche
NCT04435366 Completed

A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Interventional
See the trial
voir la fiche

NCT04423718 Active, Not recruiting

Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Interventional
See the trial
voir la fiche
NCT05384249 Recruiting, Active

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Interventional
See the trial
voir la fiche
NCT05642312 Recruiting, Active

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema

Interventional
See the trial
voir la fiche
NCT06007690 Recruiting, Active

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Interventional
See the trial
voir la fiche